人類乳癌細胞株MCF-7與子宮內膜癌細胞株Ishikawa之絲胺酸蛋白酶23於雌激素途徑不同的轉錄調控

簡易檢索 / 詳目顯示

回結果列表

研究生：	柯宏儒 Ko, Hung-Ju
論文名稱：	人類乳癌細胞株MCF-7與子宮內膜癌細胞株Ishikawa之絲胺酸蛋白酶23於雌激素途徑不同的轉錄調控 Divergent transcriptional regulation of PRSS23 by estrogen signaling in MCF-7 and Ishikawa cancer cell lines
指導教授：	莊永仁 Chuang, Yung-Jen
口試委員:
學位類別：	碩士 Master
系所名稱：	生命科學暨醫學院 - 生物資訊與結構生物研究所 Institute of Bioinformatics and Structural Biology
論文出版年：	2011
畢業學年度：	99
語文別：	英文
論文頁數：	39
中文關鍵詞：	雌激素、雌激素受體、乳癌、子宮內膜癌、絲胺酸蛋白酶23 、他莫昔芬
外文關鍵詞：	estrogen, estrogen receptor, breast cancer, endometrial cancer, PRSS23/SPUVE, tamoxifen
相關次數：	點閱：3 下載：0
分享至:	分享至facebook 分享至twitter

查詢本校圖書館目錄查詢臺灣博碩士論文知識加值系統勘誤回報

背景: 絲胺酸蛋白酶23是屬於肽酶S1家族之新穎蛋白。先前研究指出絲胺酸蛋白酶23在乳癌、甲狀腺癌、前列腺癌等癌症中有高度表現。然而，絲胺酸蛋白酶23在這些癌症之分子機制仍待證實。本實驗室先前的研究結果顯示，在表現雌激素受體甲型之乳癌細胞株(MCF-7)中，絲胺酸蛋白酶23會受到雌激素調控並且影響細胞之增生。另外，利用免疫組織染色法發現，絲胺酸蛋白酶23亦會表現於第一型子宮內膜腺癌中。因此，本研究乃探討子宮內膜癌細胞株中，絲胺酸蛋白酶23是否亦受到雌激素調控且影響其細胞之增生。

結果: 本研究發現絲胺酸蛋白酶23亦會表現於雌激素受體甲型的人類子宮內膜癌細胞株- Ishikawa。進一步以核酸干擾系統之方式，評估Ishikawa細胞中的絲胺酸蛋白酶23之功能。然而，此方法則無法有效運用以研究絲胺酸蛋白酶23之功能。另外，MCF-7細胞在雌激素作用下，絲胺酸蛋白酶23之表現量會上升。這樣的現象在Ishikawa細胞，其基因表現量則無明顯改變。另一方面，MCF-7和Ishikawa細胞在TPA作用下，絲胺酸蛋白酶23之基因表現量皆會上升，此結果暗示著絲胺酸蛋白酶23可能會受到AP-1轉錄因子的調控。本研究進一步利用生物資訊學方法分析絲胺酸蛋白酶23之上游啟動子區域，發現該區域含有轉錄因子AP-1轉錄因子結合區域 (TPA-response element; TRE)。綜合上述結果，在MCF-7細胞中，絲胺酸蛋白酶23活化可能會透過雌激素受體甲型之訊息傳遞路徑。然而，Ishikawa細胞中，絲胺酸蛋白酶23則可能是雌激素非依賴性且經由AP-1轉錄因子所活化。本篇論文研究結果顯示，在乳癌與子宮內膜癌細胞株中，雌激素之於絲胺酸蛋白酶23的轉錄調控是具有組織特異性。

Background: Serine protease 23 (PRSS23) is a novel serine protease belong to the peptidase S1 family. Previous studies indicated that PRSS23 could be highly expressed in various cancers such as breast, thyroid and prostate tumors. However, the underlying mechanism of PRSS23 in tumor progression remains unclear. Our previous study indicated that PRSS23 is a downstream estrogen effector gene and mediates the proliferation of estrogen receptor positive breast cancer cells. We found that PRSS23 was also expressed in endometrioid adenocarcinoma by immunohistochemistry staining. This thesis study thus aims to investigate whether PRSS23 could be regulated by estrogen in endometrial cancer and affects its cell proliferation.

Results: I found that PRSS23 was expressed in estrogen receptor positive human endometrial cancer cell line - Ishikawa. I further investigated the function of PRSS23 in Ishikawa cells by RNA inference systems. However, the RNA inference systems failed to generate PRSS23 knockdown Ishikawa cells. The gene expression of PRSS23 could be up-regulated under estrogen stimulation in MCF-7 cells, but not in Ishikawa cells. On the other hand, PRSS23 could be up-regulated in MCF-7 and Ishikawa cells under TPA (12-O-tetradecanoylphorbol-13-acetate)-induced AP-1(Activator protein-1) trans-activation. This is supported by the finding that the upstream promoter region of PRSS23 contains AP-1 protein binding site (TPA-response element; TRE) by bioinformatic prediction. Taken together, the possible transcriptional regulation of PRSS23 in MCF-7 cells might be regulated via ER□ dependent pathways. On the other hand, PRSS23 in Ishikawa cells might be regulated through estrogen but AP-1 dependent pathways. This study reveals the striking tissue specificity with distinct transcriptional regulation of PRSS23 by estrogen signaling in breast and endometrial cancer.

List of Contents:
中文摘要    I
Abstract    II
誌謝    III
1. Introduction    1
1.1 Preliminary outline    1
1.2 Estrogen, estrogen receptor and its mechanism    1
1.3 Estrogen related female cancer- breast cancer and endometrial cancer    3
1.4 The findings of PRSS23 in previous study and breast cancer    4
1.5 The hypothesis and objective of this study    5
2. Material and Methods    6
2.1 Cell cultures of MCF-7, Ishikawa, HEC-1B and TLA-HEK293T    6
2.2 Cell culture in hormone deprived medium    6
2.3 RNA isolation, First strand cDNA synthesis and Real-Time quantitative PCR    7
2.4 Western blotting    8
2.5 Small interfering RNAs (siRNAs)    9
2.6 Lentiviral short hairpin RNA    10
2.7 BrdU cell proliferation assay    10
2.8 Statistical analysis    11
3. Results    12
3.1 PRSS23 expressed in ER□ positive endometrial cancer line    12
3.2 The knockdown system of PRSS23 in Ishikawa cells cannot be established to investigate its function on cell proliferation    13
3.3 PRSS23 might be regulated by steroid hormones in Ishikawa cells    14
3.4 E2 stimulates PRSS23 expression in MCF-7, but not in Ishikawa cells    14
3.5 PRSS23 was up-regulated under TPA induction in MCF-7 and Ishikawa cells    15
4. Discussion    16
4.1 Experimental approach to study the function of PRSS23 in Ishikawa cells    16
4.2 The limitation of BrdU cell proliferation assay    17
4.3 Differential transcriptional regulation of PRSS23 in breast cancer and endometrial cancer    18
5. References    20
List of Table:
Table 1: Real-Time quantitative PCR primer sequence of human genes    25
Table 2: Antibodies list    26
Table 3: The predicted transcription factor binding sites in PRSS23 upstream region    27
List of Figure:
Figure 1: Survey of PRSS23 and ER□ expression in endometrial cancer lines    28
Figure 2: PRSS23 siRNA has no effect on Ishikawa cell proliferation    29
Figure 3: MCF-7 and Ishikawa cells were transduced by the medium containing lentiviral particle    30
Figure 4: The protein expression level of PRSS23 was declined in hormone deprived medium in Ishikawa cells    31
Figure 5: Effects of E2 treatment on PRSS23 expression of MCF-7 and Ishikawa cells    32
Figure 6: Effects of tamoxifen treatment on PRSS23 expression of MCF-7 and Ishikawa cells    33
Figure 7: The gene expression of EGR3 in Ishikawa cells    34
Figure 8: Effects of TPA treatment on PRSS23 expression of MCF-7 and Ishikawa cells    35
Figure 9: E2 had no stimulatory effect on the cell proliferation of Ishikawa    36
List of Supplementary Figure:
Supplementary Figure 1: Immunohistochemical detection of PRSS23 in endometrioid adenocarcinoma    37
Supplementary Figure 2: Knockdown of PRSS23 led to reduced cell proliferation in MCF-7 cells    38
Supplementary Figure 3: The possible roles of PRSS23 in breast and endometrial cancer    39

                                

5. References
1. Coser, K. R., Chesnes, J., Hur, J., Ray, S., Isselbacher, K. J., and Shioda, T. (2003) Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray, Proc Natl Acad Sci U S A 100, 13994-13999.
2. Furr, B. J., and Jordan, V. C. (1984) The pharmacology and clinical uses of tamoxifen, Pharmacol Ther 25, 127-205.
3. MacGregor, J. I., and Jordan, V. C. (1998) Basic guide to the mechanisms of antiestrogen action, Pharmacol Rev 50, 151-196.
4. Jordan, V. C. (2003) Tamoxifen: a most unlikely pioneering medicine, Nat Rev Drug Discov 2, 205-213.
5. Hochner-Celnikier, D., Greenfield, C., Finci-Yeheskel, Z., Milwidsky, A., Gutman, A., Goldman-Wohl, D., Yagel, S., and Mayer, M. (1997) Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells, Mol Hum Reprod 3, 1019-1027.
6. Myers, S. A., and Clements, J. A. (2001) Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE, J Clin Endocrinol Metab 86, 2323-2326.
7. Gustafsson, J. A. (2003) What pharmacologists can learn from recent advances in estrogen signalling, Trends Pharmacol Sci 24, 479-485.
8. Evans, R. M. (1988) The steroid and thyroid hormone receptor superfamily, Science 240, 889-895.
9. Giguere, V., Tremblay, A., and Tremblay, G. B. (1998) Estrogen receptor beta: re-evaluation of estrogen and antiestrogen signaling, Steroids 63, 335-339.
10. Matthews, J., and Gustafsson, J. A. (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta, Mol Interv 3, 281-292.
11. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., and Gustafsson, J. A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta, Endocrinology 138, 863-870.
12. Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., and Gustafsson, J. A. (2001) Mechanisms of estrogen action, Physiol Rev 81, 1535-1565.
13. Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Strom, A., Treuter, E., Warner, M., and Gustafsson, J. A. (2007) Estrogen receptors: how do they signal and what are their targets, Physiol Rev 87, 905-931.
14. Hall, J. M., Couse, J. F., and Korach, K. S. (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling, J Biol Chem 276, 36869-36872.
15. Bjornstrom, L., and Sjoberg, M. (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes, Mol Endocrinol 19, 833-842.
16. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and Webb, P. (2000) Estrogen receptor pathways to AP-1, J Steroid Biochem Mol Biol 74, 311-317.
17. Safe, S., and Kim, K. (2004) Nuclear receptor-mediated transactivation through interaction with Sp proteins, Prog Nucleic Acid Res Mol Biol 77, 1-36.
18. Kalaitzidis, D., and Gilmore, T. D. (2005) Transcription factor cross-talk: the estrogen receptor and NF-kappaB, Trends Endocrinol Metab 16, 46-52.
19. Segars, J. H., and Driggers, P. H. (2002) Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes, Trends Endocrinol Metab 13, 349-354.
20. Bunone, G., Briand, P. A., Miksicek, R. J., and Picard, D. (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBO J 15, 2174-2183.
21. Smith, C. L. (1998) Cross-talk between peptide growth factor and estrogen receptor signaling pathways, Biol Reprod 58, 627-632.
22. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., and Nakshatri, H. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance, J Biol Chem 276, 9817-9824.
23. Driggers, P. H., and Segars, J. H. (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling, Trends Endocrinol Metab 13, 422-427.
24. Veronesi, U., Boyle, P., Goldhirsch, A., Orecchia, R., and Viale, G. (2005) Breast cancer, Lancet 365, 1727-1741.
25. Martin, A. M., and Weber, B. L. (2000) Genetic and hormonal risk factors in breast cancer, J Natl Cancer Inst 92, 1126-1135.
26. Vargo-Gogola, T., and Rosen, J. M. (2007) Modelling breast cancer: one size does not fit all, Nat Rev Cancer 7, 659-672.
27. Key, T. J., Verkasalo, P. K., and Banks, E. (2001) Epidemiology of breast cancer, Lancet Oncol 2, 133-140.
28. Sommer, S., and Fuqua, S. A. (2001) Estrogen receptor and breast cancer, Semin Cancer Biol 11, 339-352.
29. Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., Runowicz, C. D., James, J. M., Ford, L. G., and Wolmark, N. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst 97, 1652-1662.
30. Jordan, V. C. (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer, Br J Pharmacol 147 Suppl 1, S269-276.
31. Veronesi, U., Maisonneuve, P., Rotmensz, N., Bonanni, B., Boyle, P., Viale, G., Costa, A., Sacchini, V., Travaglini, R., D'Aiuto, G., Oliviero, P., Lovison, F., Gucciardo, G., del Turco, M. R., Muraca, M. G., Pizzichetta, M. A., Conforti, S., and Decensi, A. (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy, J Natl Cancer Inst 99, 727-737.
32. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse, Cancer Res 48, 812-815.
33. Swerdlow, A. J., and Jones, M. E. (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study, J Natl Cancer Inst 97, 375-384.
34. Purdie, D. M., and Green, A. C. (2001) Epidemiology of endometrial cancer, Best Pract Res Clin Obstet Gynaecol 15, 341-354.
35. Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., and Vergote, I. (2005) Endometrial cancer, Lancet 366, 491-505.
36. Siiteri, P. K. (1978) Steroid hormones and endometrial cancer, Cancer Res 38, 4360-4366.
37. Miyakoshi, K., Murphy, M. J., Yeoman, R. R., Mitra, S., Dubay, C. J., and Hennebold, J. D. (2006) The identification of novel ovarian proteases through the use of genomic and bioinformatic methodologies, Biol Reprod 75, 823-835.
38. Wahlberg, P., Nylander, A., Ahlskog, N., Liu, K., and Ny, T. (2008) Expression and localization of the serine proteases high-temperature requirement factor A1, serine protease 23, and serine protease 35 in the mouse ovary, Endocrinology 149, 5070-5077.
39. Jarzab, B., Wiench, M., Fujarewicz, K., Simek, K., Jarzab, M., Oczko-Wojciechowska, M., Wloch, J., Czarniecka, A., Chmielik, E., Lange, D., Pawlaczek, A., Szpak, S., Gubala, E., and Swierniak, A. (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications, Cancer Res 65, 1587-1597.
40. Ifon, E. T., Pang, A. L., Johnson, W., Cashman, K., Zimmerman, S., Muralidhar, S., Chan, W. Y., Casey, J., and Rosenthal, L. J. (2005) U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3, Cancer Cell Int 5, 19.
41. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S. M., Fu, B., Lin, M. T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., and Kinzler, K. W. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science 321, 1801-1806.
42. Moggs, J. G., Murphy, T. C., Lim, F. L., Moore, D. J., Stuckey, R., Antrobus, K., Kimber, I., and Orphanides, G. (2005) Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes, J Mol Endocrinol 34, 535-551.
43. Lippman, M. E., Rae, J. M., and Chinnaiyan, A. M. (2008) An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status, Trans Am Clin Climatol Assoc 119, 77-90; discussion 90-72.
44. Hawker, J. R., Jr. (2003) Chemiluminescence-based BrdU ELISA to measure DNA synthesis, J Immunol Methods 274, 77-82.
45. Nishida, M. (2002) The Ishikawa cells from birth to the present, Hum Cell 15, 104-117.
46. Satyaswaroop, P. G., Fleming, H., Bressler, R. S., and Gurpide, E. (1978) Human endometrial cancer cell cultures for hormonal studies, Cancer Res 38, 4367-4375.
47. Inoue, A., Omoto, Y., Yamaguchi, Y., Kiyama, R., and Hayashi, S. I. (2004) Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells, J Mol Endocrinol 32, 649-661.
48. Pentecost, B. T., Bradley, L. M., Gierthy, J. F., Ding, Y., and Fasco, M. J. (2005) Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA, Mol Cell Endocrinol 238, 9-25.
49. DeNardo, D. G., Kim, H. T., Hilsenbeck, S., Cuba, V., Tsimelzon, A., and Brown, P. H. (2005) Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes, Mol Endocrinol 19, 362-378.
50. Gong, T., Xuan, J. H., Reggins, R. B., and Clarke, R. (2009) A Systems Biology Approach to Identify Affected Regulatory and Signaling Circuits in Protein Interaction Networks, 2009 International Joint Conference on Bioinformatics, Systems Biology and Intelligent Computing, Proceedings, 297-300 636.
51. Wang, X. Y., Penalva, L. O., Yuan, H., Linnoila, R. I., Lu, J., Okano, H., and Glazer, R. I. (2010) Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival, Mol Cancer 9, 221.
52. Holinka, C. F., Anzai, Y., Hata, H., Kimmel, N., Kuramoto, H., and Gurpide, E. (1989) Proliferation and responsiveness to estrogen of human endometrial cancer cells under serum-free culture conditions, Cancer Res 49, 3297-3301.
53. Heinemeyer, T., Wingender, E., Reuter, I., Hermjakob, H., Kel, A. E., Kel, O. V., Ignatieva, E. V., Ananko, E. A., Podkolodnaya, O. A., Kolpakov, F. A., Podkolodny, N. L., and Kolchanov, N. A. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL, Nucleic Acids Res 26, 362-367.
54. Wasserman, W. W., and Sandelin, A. (2004) Applied bioinformatics for the identification of regulatory elements, Nat Rev Genet 5, 276-287.
55. Portales-Casamar, E., Thongjuea, S., Kwon, A. T., Arenillas, D., Zhao, X., Valen, E., Yusuf, D., Lenhard, B., Wasserman, W. W., and Sandelin, A. (2010) JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles, Nucleic Acids Res 38, D105-110.

全文公開日期本全文未授權公開 (校內網路)
全文公開日期本全文未授權公開 (校外網路)
全文公開日期本全文未授權公開 (國家圖書館：臺灣博碩士論文系統)

簡易檢索 / 詳目顯示

相關論文